Genetic and clinical predictors of warfarin dose requirements in African Americans

Clinical Pharmacology and Therapeutics

Volumn 87, Issue 4, 2010, Pages 459-464

  Cavallari, L H ^a   Langaee, T Y ^b   Momary, K M ^a   Shapiro, N L ^a   Nutescu, E A ^a   Coty, W A ^c   Viana, M A G ^a   Patel, S R ^a   Johnson, J A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c Osmetech Molecular Diagnostics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; APOLIPOPROTEIN E; CARBAMAZEPINE; CYTOCHROME P450; CYTOCHROME P450 2C9; CYTOCHROME P450 4F2; ENZYME; PHENYTOIN; SIMVASTATIN; UNCLASSIFIED DRUG; VITAMIN K OXIDOREDUCTASE COMPLEX SUBUNIT 1; WARFARIN;

ADULT; AFRICAN AMERICAN; ALGORITHM; ALLELE; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENETICS; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MALE; MODEL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; STROKE;

ADULT; AFRICAN AMERICANS; AGED; ALGORITHMS; ALLELES; ANTICOAGULANTS; APOLIPOPROTEINS E; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; WARFARIN;

EID: 77949873283     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2009.223     Document Type: Article

References (48)

1. Limdi, N.A. et al. Infuence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9, 511-526 (2008).
2. Kimmel, S.E. et al. Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J. 8, 53-60 (2007).
3. Absher, R.K., Moore, M.E. & Parker, M.H. Patient-specifc factors predictive of warfarin dosage requirements. Ann. Pharmacother. 36, 1512-1517 (2002).
4. Kamali, F. et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin. Pharmacol. Ther. 75, 204-212 (2004).
5. Gage, B.F. et al. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb. Haemost. 91, 87-94 (2004).
6. Scordo, M.G. et al. Infuence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin. Pharmacol. Ther. 72, 702-710 (2002).
7. Wang, D. et al. Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) afects gene expression and warfarin dose requirement. Blood 112, 1013-1021 (2008).
8. Higashi, M.K. et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287, 1690-1698 (2002).
9. Aquilante, C.L. et al. Infuence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin. Pharmacol. Ther. 79, 291-302 (2006).
10. Anderson, J.L. et al. Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116, 2563-2570 (2007).
11. Wen, M.S. et al. Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes. Clin. Pharmacol. Ther. 84, 83-89 (2008).
12. Klein, T.E. et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 360, 753-764 (2009).
13. Scordo, M.G. et al. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol. 52, 447-450 (2001).
14. Schelleman, H. et al. Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clin. Pharmacol. Ther. 81, 742-747 (2007).
15. Limdi, N.A. et al. VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics 9, 1445-1458 (2008).
16. Dickmann, L.J. et al. Identifcation and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol. Pharmacol. 60, 382-387 (2001).
17. Allabi, A.C., Gala, J.L. & Horsmans, Y. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population. Pharmacogenet. Genomics 15, 779-786 (2005).
18. Blaisdell, J. et al. Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14, 527-537 (2004).
19. Rieder, M.J. et al. Efect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N. Engl. J. Med. 352, 2285-2293 (2005).
20. Veenstra, D.L. et al. Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet. Genomics 15, 687-691 (2005).
21. Lee, S.C. et al. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population. Clin. Pharmacol. Ther. 79, 197-205 (2006).
22. McDonald, M.G., Rieder, M.J., Nakano, M., Hsia, C.H. & Rettie, A.E. CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol. Pharmacol. 75, 1337-1346 (2009).
23. Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
24. Takeuchi, F. et al. A genome-wide association study confrms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).
25. Weintraub, M.S., Eisenberg, S. & Breslow, J.L. Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E. J. Clin. Invest. 80, 1571-1577 (1987).
26. Marsh, S., King, C.R., Porche-Sorbet, R.M., Scott-Horton, T.J. & Eby, C.S. Population variation in VKORC1 haplotype structure. J. Thromb. Haemost. 4, 473-474 (2006).
27. Gage, B.F. et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin. Pharmacol. Ther. 84, 326-331 (2008).
28. Caldwell, M.D. et al. Evaluation of genetic factors for warfarin dose prediction. Clin. Med. Res. 5, 8-16 (2007).
29. Sconce, E.A. et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106, 2329-2333 (2005).
30. Takahashi, H. et al. Diferent contributions of polymorphisms in VKORC1 and CYP2C9 to intra-and inter-population diferences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet. Genomics 16, 101-110 (2006).
31. Aithal, G.P., Day, C.P., Kesteven, P.J. & Daly, A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353, 717-719 (1999).
32. Perez-Andreu, V. et al. Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. Blood 113, 4977-4979 (2009).
33. Borgiani, P. et al. CYP4F2 genetic variant (rs2108622) signifcantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10, 261-266 (2009).
34. Wadelius, M. et al. Association of warfarin dose with genes involved in its action and metabolism. Hum. Genet. 121, 23-34 (2007).
35. Sconce, E.A., Daly, A.K., Khan, T.I., Wynne, H.A. & Kamali, F. APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet. Genomics 16, 609-611 (2006).
36. Kohnke, H., Scordo, M.G., Pengo, V., Padrini, R. & Wadelius, M. Apolipoprotein E (APOE) and warfarin dosing in an Italian population. Eur. J. Clin. Pharmacol. 61, 781-783 (2005).
37. Lal, S. et al. Infuence of APOE genotypes and VKORC1 haplotypes on warfarin dose requirements in Asian patients. Br. J. Clin. Pharmacol. 65, 260-264 (2008).
38. Huang, S.W. et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet. Genomics 19, 226-234 (2009).
39. Herman, D., Peternel, P., Stegnar, M., Breskvar, K. & Dolzan, V. The infuence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb. Haemost. 95, 782-787 (2006).
40. Loebstein, R. et al. Common genetic variants of microsomal epoxide hydrolase afect warfarin dose requirements beyond the efect of cytochrome P450 2C9. Clin. Pharmacol. Ther. 77, 365-372 (2005).
41. Vecsler, M. et al. Combined genetic profles of components and regulators of the vitamin K-dependent gamma-carboxylation system afect individual sensitivity to warfarin. Thromb. Haemost. 95, 205-211 (2006).
42. Rieder, M.J., Reiner, A.P. & Rettie, A.E. Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J. Thromb. Haemost. 5, 2227-2234 (2007).
43. Limdi, N.A. et al. Kidney function infuences warfarin responsiveness and hemorrhagic complications. J. Am. Soc. Nephrol. 20, 912-921 (2009).
44. Momary, K.M. et al. Factors infuencing warfarin dose requirements in African-Americans. Pharmacogenomics 8, 1535-1544 (2007).
45. Andrisin, T.E., Humma, L.M. & Johnson, J.A. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy 22, 954-960 (2002).
46. Hruska, M.W., Frye, R.F. & Langaee, T.Y. Pyrosequencing method for genotyping cytochrome P450 CYP2C8 and CYP2C9 enzymes. Clin. Chem. 50, 2392-2395 (2004).
47. Dean, F.B. et al. Comprehensive human genome amplifcation using multiple displacement amplifcation. Proc. Natl. Acad. Sci. USA 99, 5261-5266 (2002).
48. Reed, M.R. & Coty, W.A. eSensor®: a microarray technology based on electrochemical detection of nucleic acids and its application to cystic fbrosis carrier screening. In Microarrays: Preparation, Microfuidics, Detection Methods, and Biological Applications (eds. Dill, K., Liu, R. & Grodzinski, P.) 247-260 (Springer, New York, 2009).